Common Stock, par value $0.001 per share
- Symbol
- TVRD
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Tvardi Therapeutics, Inc.
TVRDNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 14, 2026, Tvardi Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the fiscal quarter ended June 30, 2026. A copy of the Company’s press release dated August 14, 2026 is attached hereto as Exhibit 99.1 and is incorporated herein by reference.…
Press release in this filing
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update →Company context
Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive uncontrolled proliferation, survival and immune dysregulation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The Company is conducting clinical trials with TTI-109 in healthy volunteers and TTI-101 in hepatocellular carcinoma (NCT05440708). To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).
Current securities
Registered securities in this filing
TVARDI THERAPEUTICS, INC. · 8-K · Filed 2026-08-14
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition.
On August 14, 2026,
Tvardi Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results and business highlights
for the fiscal quarter ended June 30, 2026. A copy of the Company’s press release dated August 14, 2026 is attached hereto
as Exhibit 99.1 and is incorporated herein by reference.
The information contained
herein and the accompanying Exhibit 99.1 is being furnished under “Item 2.02 Results of Operations and Financial Condition”
and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be
deemed incorporated by reference in any filing with the Securities and Exchange Commission made by us, whether made before or after the
date hereof, regardless of any general incorporation language in such filing.
Filed exhibits (1)
EX-99.1 2 tm2623143d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations Announced ulcerative colitis (UC) as the initial disease indication for TTI-109 and will host a KOL webinar on the clinical potential of TTI-109 in UC on August 19, 2026, at 11:00 a.m. ET HOUSTON, TX - August 14, 2026 - Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its financial and operating results for the second quarter ended June 30, 2026, and provided a business update. Recent Developments Reported topline results from the healthy volunteer study of its next-generation STAT3 inhibitor, TTI-109, confirming prodrug design, improved tolerability and pharmacodynamic evidence of STAT3 target engagement. o T…
Open exhibit ↗